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urinary levels of collagen type II C-telopeptide fragments (uCTX-
II) were measured by the CartiLaps ELISA assay. uCTX-II was
corrected by urinary creatinine levels as assessed by a standard
colorimetric method. In order to achieve approximately normal
distribution, log(uCTX-II) was used as the marker.
At BL, the distribution of KL scores was (145,88,30,24,1) for
KL 0-4. Among the BL healthy knees (KL 0), 101 were non-
progressors at FU and 25 were progressors (KL > 0) at FU.
Results: The mean total cartilage volume at BL was quantiﬁed
to 6851 mm3 with scan-rescan CV of 3.6% (the intra-scan CV
is zero since the method is fully automatic). The uCTX-II at
BL was higher for the progressors than for the non-progressors
(244 vs 173 ng/mmol, p<0.01, sample size 67, odds ratio 6.2,
Figure 1). The cartilage loss for the low uCTX-II group (less than
mean uCTX-II) at BL was lower than for the high uCTX-II group
(p=0.02, Figure 2).
Figure 1. Increased uCTX-II at BL was a predictor of early OA progression as
deﬁned by radiographic signs (increased KL score at FU from 0 at BL).
Figure 2. Increased uCTX-II at BL was a predictor of cartilage loss over 21
months.
Conclusions: Clinical trials of potential DMOADS rely on proper
selection of the study population. The selection criteria must
ensure that the population is likely to progress in OA level without
treatment - otherwise it will be impossible to show a treatment
effect for any DMOAD. The results suggested that uCTX-II is
indeed a suitable prognostic marker for use in selection criteria.
Elevated BL uCTX-II implies an increased risk of OA progression
(progressors are 41% increased, odds ratio 6.2) - deﬁned by
either KL score or by cartilage loss. Thereby, the pair of uCTX-II
and cartilage volume biomarkers seems suitable for selecting
the study population and for quantifying the treatment efﬁcacy in
clinical studies.
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Purpose: Sixty percent of synovial ﬂuids from patients with
severe osteoarthritis contain calcium pyrophosphate dihydrate
(CPPD) or basic calcium phosphate (BCP) crystals. Problems
in accurately identifying and characterizing calcium-containing
crystals have slowed progress towards understanding the role
of these pathologic crystals in osteoarthritis. Synchrotron FTIR
(sFTIR) analysis has been useful to study mineral formation in
bone. We sought to determine if it could be used in human
synovial ﬂuid and in mineralization models to identify and char-
acterize calcium-containing crystals
Methods: Discarded synovial ﬂuids containing native CPPD or
BCP crystals were obtained in accordance with our local IRB.
Biosynthetic calcium-containing crystals were generated in vitro
using well characterized models of crystal formation, including
a cell culture model with porcine articular chondrocytes and a
model utilizing isolated porcine articular cartilage vesicles. Truly
synthetic CPPD and BCP crystals were generated in our lab-
oratory in an inorganic milieu. Crystal containing material was
placed on an IR reﬂective slide. Crystal-containing areas were
identiﬁed with light microscopy, and examined with a Thermo
Fisher Continuum FTIR Microscope at the Synchrotron Radia-
tion Center in Stoughton, WI. The FTIR spectra generated were
compared with known spectra of multiple forms of pure calcium
phosphate and calcium pyrophosphate crystals, as well as spec-
tra generated with truly synthetic CPPD and BCP crystals and
cartilage proteoglycans alone and in mixtures.
Results: sFTIR readily identiﬁed both CPPD and BCP crystals
in synovial ﬂuids and in articular cartilage vesicle models. Most
CPPD crystals were monoclinic. CPPD crystals identical to those
seen in synovial ﬂuids were also readily identiﬁable in articular
chondrocyte monolayers incubated with ATP. Most of the BCP
crystals from synovial ﬂuids and models were consistent with
hydroxyapatite, rather than with the other calcium phosphate
crystals types known to be present in BCP. Interestingly, careful
examination of different regions of human or porcine material
often revealed both CPPD and BCP containing areas in a single
crystal aggregate. In spectra from many CPPD crystals, the peak
at the 1134 cm -1 frequency region found on the standard spec-
trum for CPPD was absent or diminished. Addition of cartilage
proteoglycans to truly synthetic CPPD crystals dampened the
peak at this frequency region, much as this peak was diminished
in biosynthetic or native CPPD.
Conclusions: sFTIR analysis allows for accurate identiﬁcation of
CPPD and BCP crystals generated in vivo or in vitro. These data
support the presence of mixtures of crystals in a single region,
and prove the validity of the monolayer model of CPPD crystal
formation. they demonstrate crystal-proteoglycan interaction in
vivo and in vitro. This novel application of sFTIR should further
our understanding of the role of these crystals in osteoarthritis.
